Ichnos Sciences welcomes Eric Feldman as new chief medical officer
Dr. Feldman will be responsible for all pipeline development activities, including Clinical Development, Clinical Operations, Regulatory Sciences, Pharmacokinetics and Translational Sciences, Biometrics and Drug Safety.
Additionally, he will be the Co-Chair of the R and D leadership team and will collaborate closely with the discovery and antibody engineering organizations at Ichnos' sites in Switzerland to select and set priorities for research targets.
Previously, Dr. Feldman served as Senior Vice President, Chief Medical Officer, at GlycoMimetics, leading the Phase 3 registration study of uproleselan in acute myeloid leukemia, as well as other early-stage assets.
He also served as Chief Medical Officer at Amphivena, focusing on bispecific antibody therapies for blood cancers, and directed the myeloid leukemia antibody-drug conjugate (ADC) program at Seattle Genetics, Inc.
Dr. Feldman received a medical degree at New York Medical College, and he holds a B.A. from Tulane University. ■